International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?
Drug and Alcohol Review · 2026-07 · 45 (5)
DOI: 10.1111/dar.70203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Alcohol Review, online erschienen am 15.07.2026. Verfasst von Myfanwy Graham und 3 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Dronabinol, Medical Marijuana, Cannabis. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health and Aged Care, Australian Government, National Health and Medical Research Council, Department of Health, Disability and Ageing.
Abstract (Originalsprache)
Introduction
There have been concerted research efforts internationally to examine the health effects of higher delta‐9‐tetrahydrocannabinol (THC) concentration cannabis products and to design policies to reduce potential negative health effects of their use. This study identifies international policy approaches for regulating higher THC products relevant to the Australian medicinal cannabis program.
Methods
An environmental scan of international literature and policy as part of a broader study commissioned to inform Australian policy. Methods were prospectively registered with the Open Science Framework: 10.17605/OSF.IO/HNFUT . Peer‐reviewed and grey literature on international policy approaches were identified through searches for ‘high potency THC’ and ‘policy’. The literature was then narratively synthesised.
Results
We identified 76 publications and other sources that described policy approaches recommended or implemented in five jurisdictions: Canada; Germany; the Netherlands; the United States; and Uruguay. Approaches included setting a threshold for cannabis flower THC concentration at or below the biological THC limit of 30%–35% found in the plant and a risk‐tiered model for highly concentrated THC dosage forms. THC limits per dose and per package have been applied to edible products. Additional approaches included quantity limits, packaging and labelling requirements, pharmacovigilance, and education. Discussion and Conclusions Policy approaches for higher THC concentration cannabis products could be adapted to the Australian regulatory environment to reduce potentially harmful THC exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia.
- School of Psychological Sciences and the Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
- Monash Bioethics Centre, School of Philosophy, History and International Studies, Monash University, Melbourne, Australia.
ORCID-Profile: Myfanwy Graham, Suzanne Nielsen
Förderung
- Department of Health and Aged Care, Australian Government
- National Health and Medical Research Council
- Department of Health, Disability and Ageing
Zitieren
APA
Graham, M., Assefa, D., Carter, A., & Nielsen, S. (2026). International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?. Drug and Alcohol Review, 45(5). https://doi.org/10.1111/dar.70203
Vancouver
Graham M, Assefa D, Carter A, Nielsen S. International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?. Drug and Alcohol Review. 2026;45(5). doi:10.1111/dar.70203
BibTeX
@article{Graham2026,
author = {Graham, Myfanwy and Assefa, Dereje and Carter, Adrian and Nielsen, Suzanne},
title = {International Policy Approaches for Higher THC Cannabis Products: Are They Applicable to the Australian Medicinal Cannabis Framework?},
journal = {Drug and Alcohol Review},
year = {2026},
volume = {45},
number = {5},
doi = {10.1111/dar.70203}
}
EUVIMED